Important note: Information in this article was accurate in October 2006. The state of the art may have changed since the publication date.
US adult treatment guidelines updated
HIV Treat Bull - 2006 October;7(10):
On October 10, 2006, the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents released a new revision of the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents.
Most of the changes to the previous edition (highlighted in yellow in the pdf file) relate to recommendations for preferred and alternative antiretroviral components in treatment-naïve patients and on safety data that have emerged since the last revision.
Two boosted PI-regimens have been added to recommended first-line regimens: atazanavir/ritonavir (once daily) and fosamprenavir/ritonavir (twice-daily), both plus 2 RTIs. Previous recommendations only included efavirenz plus 2 RTIs or lopinaivr/ritonavir plus 2 RTIs.
The recommendations for choice of nucleosides are fixed dose combinations of either tenofovir/FTC or AZT/3TC. Alternative options are abacavir/3TC or ddI with either 3TC or FTC.
Tables 28 and 29 have been revised according to updates in the Perinatal Guidelines to incorporate preclinical and clinical data relevant to the use of darunavir during pregnancy and new recommendations on antiretroviral use during pregnancy.
Table 30 has been updated to include information on expanded access programs for two investigational agents, TMC125 and MK-0518.
comment
It is noticeable that AZT remains a first-line preferred nucleoside and that no reference is made to the evidence linking AZT to lipoatrophy, which led to UK guidelines in July 2005 downgrading the use of AZT to that of an alternative option.
Source: FDA list serve
An archive of past list serve announcements is available on the FDA web site
2006-10-10
IB060710-16
©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.